These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15960769)

  • 21. Role of health technology assessment in shaping the benefits package in The Netherlands.
    Stolk EA; de Bont A; van Halteren AR; Bijlmer RJ; Poley MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):85-94. PubMed ID: 19371181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health technology assessment.
    Papatheofanis FJ
    Q J Nucl Med; 2000 Jun; 44(2):105-11. PubMed ID: 10967621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why ethics should be part of health technology assessment.
    Hofmann BM
    Int J Technol Assess Health Care; 2008; 24(4):423-9. PubMed ID: 18828936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obligations and marginal decisions in a fair health system.
    Berger JT
    Am J Bioeth; 2004; 4(3):123-4; discussion W40-2. PubMed ID: 16192171
    [No Abstract]   [Full Text] [Related]  

  • 25. Conditionally funded field evaluations and practical trial design within a health technology assessment framework.
    Bowen JM; Patterson LL; O'Reilly D; Hopkins RB; Blackhouse G; Burke N; Xie F; Tarride JE; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):324-31. PubMed ID: 19394573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A determination of topics for health technology assessment in Thailand: making decision makers involved.
    Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling for health care and other policy decisions: uses, roles, and validity.
    Weinstein MC; Toy EL; Sandberg EA; Neumann PJ; Evans JS; Kuntz KM; Graham JD; Hammitt JK
    Value Health; 2001; 4(5):348-61. PubMed ID: 11705125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resource allocation and health technology assessment in Australia: views from the local level.
    Gallego G; van Gool K; Kelleher D
    Int J Technol Assess Health Care; 2009 Apr; 25(2):134-40. PubMed ID: 19331706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there an alternative to a National Health Board for Technology Assessment?
    Lerner JC
    Med Interface; 1994 Jun; 7(6):123-6, 132. PubMed ID: 10135316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are economic evaluations and health technology assessments increasingly demanded in times of rationing health services? The case of the Argentine financial crisis.
    Rubinstein A; Belizán M; Discacciati V
    Int J Technol Assess Health Care; 2007; 23(2):169-76. PubMed ID: 17493302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision tools in health care: focus on the problem, not the solution.
    Liu J; Wyatt JC; Altman DG
    BMC Med Inform Decis Mak; 2006 Jan; 6():4. PubMed ID: 16426446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare rationing. Decision time.
    Moore A
    Health Serv J; 2011 May; 121(6255):22-3. PubMed ID: 21682223
    [No Abstract]   [Full Text] [Related]  

  • 34. Policy making and roles of health technology assessment.
    Tantivess S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S88-99. PubMed ID: 19253491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to introduce more (or better) ethical arguments in HTA?
    Schokkaert E
    Int J Technol Assess Health Care; 2015 Jan; 31(3):111-2. PubMed ID: 26044817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE.
    Goetghebeur MM; Wagner M; Samaha D; O'Neil W; Badgley D; Castro-Jaramillo H; Abrishami P; Sarria-Santamera A; Cleemput I; Tringali M
    Int J Technol Assess Health Care; 2017 Jan; 33(4):504-520. PubMed ID: 29019295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic considerations for health insurance coverage of emerging genetic tests.
    Giacomini M; Miller F; O'Brien BJ
    Community Genet; 2003; 6(2):61-73. PubMed ID: 14560066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis.
    Torbica A; Fornaro G; Tarricone R; Drummond MF
    Value Health; 2020 Jan; 23(1):17-24. PubMed ID: 31952668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DECISION-MAKING ALIGNED WITH RAPID-CYCLE EVALUATION IN HEALTH CARE.
    Schneeweiss S; Shrank WH; Ruhl M; Maclure M
    Int J Technol Assess Health Care; 2015 Jan; 31(4):214-22. PubMed ID: 26585440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technology assessment and resource allocation for predictive genetic testing: a study of the perspectives of Canadian genetic health care providers.
    Adair A; Hyde-Lay R; Einsiedel E; Caulfield T
    BMC Med Ethics; 2009 Jun; 10():6. PubMed ID: 19538750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.